| 000 | 01618 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513171159.0 | ||
| 264 | 0 | _c19990407 | |
| 008 | 199904s 0 0 eng d | ||
| 022 | _a0003-9926 | ||
| 024 | 7 |
_a10.1001/archinte.159.6.593 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGrover, S A | |
| 245 | 0 | 0 |
_aCost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. _h[electronic resource] |
| 260 |
_bArchives of internal medicine _cMar 1999 |
||
| 300 |
_a593-600 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aCanada |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xeconomics |
| 650 | 0 | 4 |
_aCerebrovascular Disorders _xeconomics |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDrug Costs |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xeconomics |
| 650 | 0 | 4 |
_aHypolipidemic Agents _xeconomics |
| 650 | 0 | 4 | _aLife Expectancy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRisk |
| 650 | 0 | 4 | _aScandinavian and Nordic Countries |
| 650 | 0 | 4 | _aSensitivity and Specificity |
| 650 | 0 | 4 |
_aSimvastatin _xeconomics |
| 700 | 1 | _aCoupal, L | |
| 700 | 1 | _aPaquet, S | |
| 700 | 1 | _aZowall, H | |
| 773 | 0 |
_tArchives of internal medicine _gvol. 159 _gno. 6 _gp. 593-600 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1001/archinte.159.6.593 _zAvailable from publisher's website |
| 999 |
_c10049848 _d10049848 |
||